SCHEMBL9907424

SCHEMBL9907424

COC(=O)c1cc(C)c2nccc(-c3c(F)cc(F)cc3F)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.39
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TNF P01375 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
NOD2 Q9HC29 1/20 0.38
NOD1 Q9Y239 1/20 0.38
PDK2 Q15119 1/20 0.37
KDM4E B2RXH2 3/20 0.36
HTR5A P47898 2/20 0.36
KDM6B O15054 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907468 0.93 PTGDR2 (0.39) MAPK14LMNAMAPTMEN1ALDH1A1
SCHEMBL9907483 0.92 MAPK14 (0.37) MAPK14LMNAMAPTSMN1; SMN2MEN1
SCHEMBL9909254 0.91 GRM2 (0.37) MAPK14LMNAMAPTALDH1A1GAA
SCHEMBL9907417 0.91 PTGDR2 (0.42) MAPK14ALDH1A1PDK2KDM4EHTR5A
SCHEMBL9907456 0.90 LMNA (0.42) MAPK14LMNAMAPTSMN1; SMN2MEN1
SCHEMBL9907426 0.87 ACLY (0.40) MAPK14LMNAMAPTSMN1; SMN2MEN1
SCHEMBL9907431 0.87 MAPK14 (0.51) MAPK14LMNAMAPTSMN1; SMN2KDM4E
SCHEMBL9907418 0.86 HTR5A (0.41) MAPK14HTR5AKDM4CPTGDR2CYP2C9
SCHEMBL9907519 0.86 PDK2 (0.35) MAPK14LMNAMAPTALDH1A1GAA
SCHEMBL9907458 0.85 PTGDR2 (0.41) LMNAMAPTSMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E MAPK14 3810/4885LMNA 4287/4885MAPT 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.